Experts: Warren’s Anti-Corruption Plan Ignores Complex FDA Reg Process

By Beth Wang / November 13, 2019 at 5:06 PM
Three FDA experts say 2020 presidential hopeful Sen. Elizabeth Warren’s (D-MA) plan to weed out government corruption by restricting how companies share data and information with federal agencies could have a chilling effect on FDA and regulated industries. The plan aims to hold companies accountable when they mislead the public and share false information to federal regulators, and prevent companies from submitting non-peer-reviewed, industry-funded research. However, the experts tell Inside Health Policy the plan fails to take into account...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.